NASDAQ:MRTX

Mirati Therapeutics Stock Forecast, Price & News

$157.13

-2.20 (-1.38 %)

(As of 07/23/2021 12:00 AM ET)

Add

Compare

Today's Range

$153.84

▼

$159.77

50-Day Range

$149.50

▼

$172.25

52-Week Range

$115.44

▼

$249.42

Volume272,985 shs

Average Volume640,067 shs

Market Capitalization$8.08 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.33

30 days | 90 days | 365 days | Advanced Chart

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Mirati Therapeutics

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Mirati Therapeutics (NASDAQ:MRTX) Shares Down 4.8%
June 29, 2021 | americanbankingnews.com

Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
June 28, 2021 | finance.yahoo.com

Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation
June 25, 2021 | finance.yahoo.com

Mirati Therapeutics' Adagrasib Gets Breakthrough Therapy Designation
June 24, 2021 | markets.businessinsider.com

Hedge Funds Still Buying Mirati Therapeutics, Inc. (MRTX)
June 17, 2021 | finance.yahoo.com

Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
May 6, 2021 | markets.businessinsider.com

Were Hedge Funds Right About Piling Into Mirati Therapeutics (MRTX)?
May 4, 2021 | finance.yahoo.com

Is Mirati Therapeutics (MRTX) Stock A Buy or Sell?
March 23, 2021 | finance.yahoo.com

Mirati Therapeutics, Inc. (26M.F)
March 20, 2021 | ca.finance.yahoo.com

7 Pharmaceutical Stocks Working on Their Next Blockbuster
March 12, 2021 | markets.businessinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
Previous Symbol
CUSIPN/A
CIK1576263
Webwww.mirati.com
Phone858-332-3410
Employees199
Year FoundedN/A

Sales & Book Value

Annual Sales$13.40 million
Price / Sales603.19
Cash FlowN/A
Price / Cash FlowN/A
Book Value$26.98 per share
Price / Book5.82

Profitability

EPS (Most Recent Fiscal Year)($7.96)
Net Income$-357,940,000.00
Net MarginsN/A
Return on Equity-43.11%
Return on Assets-39.31%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares51,440,000
Market Cap$8.08 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.24 out of 5 stars

Medical Sector

963rd out of 2,215 stocks

Pharmaceutical Preparations Industry

464th out of 867 stocks

3.3 Analyst's Opinion

Consensus Rating
Mirati Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 10 buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $217.92, Mirati Therapeutics has a forecasted upside of 38.7% from its current price of $157.13.
Amount of Analyst Coverage
Mirati Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Mirati Therapeutics has received 427 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Mirati Therapeutics has received 306 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Mirati Therapeutics has received 58.25% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote “Outperform” if you believe MRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Mirati Therapeutics does not currently pay a dividend.
Dividend Growth
Mirati Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mirati Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,685,538.00 in company stock.
Percentage Held by Insiders
Only 3.12% of the stock of Mirati Therapeutics is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Mirati Therapeutics are expected to decrease in the coming year, from ($10.25) to ($10.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mirati Therapeutics is -18.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mirati Therapeutics is -18.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mirati Therapeutics has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

Is Mirati Therapeutics a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Mirati Therapeutics?

Wall Street analysts have given Mirati Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mirati Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 3,440,000 shares, a decline of 28.0% from the June 15th total of 4,780,000 shares. Based on an average daily trading volume, of 594,300 shares, the short-interest ratio is currently 5.8 days. Currently, 7.1% of the shares of the stock are short sold.
View Mirati Therapeutics' Short Interest.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Mirati Therapeutics.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($2.67) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.13) by $0.54. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.17 million. The business's quarterly revenue was down 96.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.02) earnings per share.
View Mirati Therapeutics' earnings history.

How has Mirati Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRTX shares have increased by 103.1% and is now trading at $157.13.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MRTX?

15 analysts have issued 1-year price objectives for Mirati Therapeutics' stock. Their forecasts range from $160.00 to $285.00. On average, they anticipate Mirati Therapeutics' share price to reach $217.92 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price.
View analysts' price targets for Mirati Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:

Dr. Charles M. Baum, Pres, CEO & Director (Age 63, Pay $1.13M)
Mr. Daniel R. Faga, Chief Operating Officer (Age 41, Pay $1.16M)
Dr. James G. Christensen, Chief Scientific Officer (Age 53, Pay $820.05k)
Mr. Benjamin J. Hickey, Chief Commercial Officer (Age 45, Pay $798.32k)
Ms. Vickie S. Reed, Sr. VP & Chief Accounting Officer (Age 59)
Temre Johnson, Director of Investor Relations & Corp. Communications
Ms. Reena R. Desai, Gen. Counsel & Corp. Sec.
Ms. Kristin Gustafson, Chief HR Officer
Dr. Kelly Covello Ph.D., VP & Head of Medical Affairs
Mr. Ryan Asay, VP & Head of Corp. Affairs

Who are some of Mirati Therapeutics' key competitors?

Some companies that are related to Mirati Therapeutics include Genmab A/S (GMAB), BeiGene (BGNE), Shiseido (SSDOY), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Catalent (CTLT), Elanco Animal Health (ELAN), Viatris (VTRS), Zai Lab (ZLAB) and BioMarin Pharmaceutical (BMRN).
View all of MRTX's competitors.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $157.13.

How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of $8.08 billion and generates $13.40 million in revenue each year. The biotechnology company earns $-357,940,000.00 in net income (profit) each year or ($7.96) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

Mirati Therapeutics employs 199 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

Where are Mirati Therapeutics' headquarters?

Mirati Therapeutics is headquartered at 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]

This page was last updated on 7/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here